<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514955</url>
  </required_header>
  <id_info>
    <org_study_id>IMRT / 25027</org_study_id>
    <secondary_id>ACRI PILOT GRANT</secondary_id>
    <nct_id>NCT01514955</nct_id>
  </id_info>
  <brief_title>An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer</brief_title>
  <acronym>IMRT</acronym>
  <official_title>An Initial Feasibility Study to Integrate High-precision, Image Guided, Radiotherapy(MRI Based Brachytherapy and CT/MRI Fused Dynamic IMRT Planning) in the Treatment Planning of 10 Patients With Locally Advanced Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main cause of mortality in cervix cancer is local relapse in the pelvis. Since distant&#xD;
      metastasis is quiet rare, increasing local control in the pelvis can directly translate into&#xD;
      improvement in survival. Obstacles in front of this approach is the dose limitation to normal&#xD;
      organs located in the pelvis adjacent to the tumor. 3-D MRI based EBRT and Brachytherapy will&#xD;
      grant safe delivery of more conformal higher doses of radiation to the tumor and allowing&#xD;
      sparing of the normal structures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 10 patients with a diagnosis of locally advanced cervical carcinoma will be&#xD;
      enrolled. After diagnosis and written informed consent, patients will undergo investigations&#xD;
      prior to treatment planning, including CT imaging as per standard of care. In addition,&#xD;
      patients will have an MRI of the pelvis + PET scan + EUA and gold seeds insertion to verify&#xD;
      pelvic organs movement and EB-IMRT with daily cone beam CT. Brachytherapy treatment planning&#xD;
      will be based on MRI imaging with the applicator in situ.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility parameters</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, acute and late toxicity, local control rate, survival</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetric comparison between 2D and 3D Brachytherapy treatment planning</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Integrated MRI Based RT as Standard of Care</condition>
  <condition>Locally Advanced Cervical Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gold seeds insertion to detect movements at pelvis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Image guided MRI based RT (IMRT+Brachytherapy)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer of the uterine cervix considered suitable for curative treatment with&#xD;
             definitive radio-chemo-therapy including MRI guided BT. (stage IB2 bulky disease-stage&#xD;
             IVa)&#xD;
&#xD;
          -  Staging according to FIGO and TNM guidelines&#xD;
&#xD;
          -  Positive biopsy showing squamous cell carcinoma, adenocarcinoma or adeno-squamous cell&#xD;
             carcinoma of the uterine cervix&#xD;
&#xD;
          -  No pelvic nodes &gt; 2cm&#xD;
&#xD;
          -  MRI of pelvis at diagnosis&#xD;
&#xD;
          -  MRI of the retroperitoneal space and abdomen at diagnosis&#xD;
&#xD;
          -  MRI with applicator in place at time of BT&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  Patient informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pelvic nodes &gt; 2cm&#xD;
&#xD;
          -  Previous pelvic or abdominal radiotherapy&#xD;
&#xD;
          -  Previous total or partial hysterectomy&#xD;
&#xD;
          -  Combination of preoperative radiotherapy with surgery&#xD;
&#xD;
          -  Patients receiving neo-adjuvant chemotherapy&#xD;
&#xD;
          -  Patients receiving BT only&#xD;
&#xD;
          -  Contraindications to MRI&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

